Accounting for the drug life cycle and future drug prices in cost-effectiveness analysis

PharmacoEconomics

Volumn 29, Issue 1, 2011, Pages 1-15

  Hoyle, Martin ^a  

^a UNIVERSITY OF EXETER   (United Kingdom)

Author keywords

Cost effectiveness; Discount rate; Drug cost.

Indexed keywords

ALPHA INTERFERON; BEVACIZUMAB; CAPTOPRIL; CARMUSTINE; CINACALCET; IMATINIB; ISOSORBIDE MONONITRATE; LOFEPRAMINE; PRAVASTATIN; RANITIDINE; SALMETEROL; SORAFENIB; SUNITINIB; TEMSIROLIMUS;

ANGINA PECTORIS; ASTHMA; CANCER RADIOTHERAPY; CANCER SURGERY; CARDIOVASCULAR DISEASE; CHRONIC MYELOID LEUKEMIA; CHRONIC OBSTRUCTIVE LUNG DISEASE; COST EFFECTIVENESS ANALYSIS; DEPRESSION; DRUG COST; DRUG EFFICACY; GLIOMA; HYPERPARATHYROIDISM; HYPERTENSION; KIDNEY CARCINOMA; KIDNEY FAILURE; MATHEMATICAL MODEL; MATHEMATICS; NEW ZEALAND; PEPTIC ULCER; PRESCRIPTION; PRIORITY JOURNAL; REVIEW; UNITED KINGDOM;

COST-BENEFIT ANALYSIS; DRUG COSTS; GREAT BRITAIN; HUMANS;

EID: 78650187909     PISSN: 11707690     EISSN: 11792027     Source Type: Journal    
DOI: 10.2165/11584230-000000000-00000     Document Type: Review

References (19)

1. National Institute for Health and Clinical Excellence. Guide to the methods of technology appraisal. London: NICE, 2008
2. Hoyle M, Anderson R. Whose costs and benefits? Why economic evaluations should simulate both prevalent and all future incident patient cohorts. Med Decis Making 2010 Jul-Aug; 30 (4): 426-37
3. Hoyle M. Future drug prices and cost-effectiveness analyses. Pharmacoeconomics 2008; 26 (7): 589-602
4. Pharmaceutical Management Agency. Pharmacoeconomics: Prescription For Pharmacoeconomic Analysis (PFPA). Wellington: PHARMAC, 2007 [online]. Available from URL: http://www.pharmac.govt.nz/EconomicAnalysis/pharma coeconomics [Accessed 2009 Feb 1]
5. Grabowski HG, Vernon JM. Brand loyalty, entry, and price-competition in pharmaceuticals after the 1984 Drug Act. J Law Econ 1992; 35 (2): 331-50
6. Luce BR, Manning WG, Siegel JE, et al. Estimating costs in cost-effectiveness analysis. In: Gold MR, Siegel JE, Russell LB, et al., editors. Cost-effectiveness in health and medicine. New York: Oxford University Press, 1996: 176-213
7. Garrison LP, Mansley EC, Abbott TA, et al. Good research practices for measuring drug costs in cost-effectiveness analyses: a societal perspective. The ISPOR Drug Cost Task Force report: part II. Value Health 2010; 13 (1): 8-13
8. International Society for Pharmacoeconomics and Outcomes Research. Comparative table (compare selected countries on selected key features) [online]. Available from URL: http://www.ispor.org/PEguidelines/COMP1.asp [Accessed 2009 Nov 1]
9. Salomon JA, Weinstein MC, Goldie SJ. Taking account of future technology in cost effectiveness analysis. BMJ 2004; 329 (7468): 733-6
10. Danzon PM, Kim JD. The life cycle of pharmaceuticals: a cross-national perspective. London: Office of Health Economics, 2002 [online]. Available from URL: http://hc. wharton.upenn.edu/danzon/html/books-and-monographs. htm [Accessed 2008 Oct 15]
11. Thompson Coon J, Hoyle M, Green C, et al. Bevacizumab, sorafenib tosylate, sunitinib and temsirolimus for renal cell carcinoma: a systematic review and economic evaluation. Health Technol Assess 2010; 14 (2): 1-184, iii-iv
12. NHS: The Information Centre. Prescription cost analysis 2008 [online]. Available from URL: http://www.ic.nhs.uk/ statistics-and-data-collections/ primary-care/prescriptions/ prescription-cost-analysis-2008 [Accessed 2009 Nov 13]
13. Office of Fair Trading. The pharmaceutical price regulation scheme: an OFT market study. London: Office of Fair Trading, 2007 [online]. Available from URL: http://www. oft.gov.uk/shared-oft/reports/comp-policy/oft885.pdf [Accessed 2008 Oct 23]
14. National Institute for Health and Clinical Excellence. Published appraisals. London: NICE, 2009 [online]. Available from URL: http://www.nice.org.uk/guidance/index.jsp?action= byType&type=6&status=3 [Accessed 2010 Feb 23]
15. Garber AM, Weinstein MC, Torrance GW, et al. Theoretical foundations of cost-effectiveness analysis. In: Gold MR, Siegel JE, Russell LB, et al., editors. Cost-effectiveness in health and medicine. New York: Oxford University Press, 1996: 25-53
16. Shih YCT, Han S, Cantor SB. Impact of generic drug entry on cost-effectiveness analysis. Med Decis Making 2005; 25 (1): 71-80
17. Department of Health. Pharmaceutical Price Regulation Scheme. London: Department of Health, 2009 [online]. Available from URL: http://www.dh.gov.uk/ pprs [Accessed 2010 Jan 3]
18. Bond M, Mealing S, Anderson R, et al. The effectiveness and cost-effectiveness of cochlear implants for severe to profound deafness in children and adults: a systematic review and economic model. Health Technol Assess 2009; 13 (44): 1-330
19. McCabe C, Claxton K, Culyer AJ. The NICE costeffectiveness threshold: what it is and what that means. Pharmacoeconomics 2008; 26 (9): 733-44